Cerus Investor Relations Material
Latest events
Q1 2025
Cerus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cerus Corporation
Access all reports
Cerus Corporation operates as a biomedical products company. The company focuses on controlling the intrinsic systemic risk of blood transfusion. Its INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, like viruses, bacteria and parasites that may be present in donated blood. The INTERCEPT red blood cell system is designed to inactivate blood-borne pathogens in donated red blood cells, white blood cells, and platelets. The system works by disrupting nucleic acids inside pathogens without affecting the viability or functionality of the red blood cells, white blood cells, or platelets.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
CERS
Country
🇺🇸 United States